" Korean versions of Wegovy and Mounjaro are coming"... Hanmi Science Surges More Than 10% in After-Hours Trading
Hanmi Pharmaceutical's GLP-1 Obesity Drug Receives Product Approval
Hanmi Science, the holding company of the Hanmi Pharmaceutical Group, is surging more than 10% in after-hours trading on Oct. 7.
As of 6:10 p.m. on Oct. 7, Hanmi Science was trading at 64,000 won, up 10.15% from its regular-session closing price of 58,100 won.
Hanmi Science is the operating holding company of the Hanmi Pharmaceutical Group, whose affiliates include Hanmi Pharmaceutical, Online Pharm, and JVM, a company specializing in automated pharmaceutical dispensing systems. Its main sources of revenue include managing affiliates, income from equity stakes, and patent and brand royalties. It also operates healthcare and pharmaceutical distribution businesses.
Hot Picks Today
"'Cheaper Direct-Run Rest Stops,' We Thought... 'Pay 700 Million Won and We'll Hand It Over and Leave,' Operators Fume; Not This Year"
- "Wasn't It Supposed to Be Gone? Alarming Surge in Cases Leads US to Declare Disaster Emergency"
- After 17 Tardies, AI Says, "We Should Fire This One, Right?" ... Outcry as U.S. Puts Brakes on 'Robot Bosses'
- "Weekly Work Cap for Time-Selective Civil Servants Should Be Raised to 40 Hours," Park Jeonghyeon Says at Parliamentary Audit
- Park Jinyoung: "I've Never Worked for President Lee or the Democratic Party... A Valuable Opportunity for Our Sons, Daughters and Nieces and Nephews" [2026 National Assembly Audit]
The stock is believed to be gaining after news broke that Epeoto Injector, a new GLP-1 obesity treatment developed in-house by Hanmi Pharmaceutical, received product approval from the Ministry of Food and Drug Safety. Hanmi Pharmaceutical is preparing to launch the drug with the goal of supplying it in South Korea by the end of the year.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.